Literature for LY3000328 (C01.034 inhibitor)

(Topics flags: I Inhibitor. To select only the references relevant to a single topic, click the link above. See explanation.)

2017
1. Yan,X., Wu,C., Chen,T., Santos,M.M., Liu,C.L., Yang,C., Zhang,L., Ren,J., Liao,S., Guo,H., Sukhova,G.K. and Shi,G.P.
   Cathepsin S inhibition changes regulatory T-cell activity in regulating bladder cancer and immune cell proliferation and apoptosis
   Mol Immunol82, 66-74. PubMed  Europe PubMed DOI  I
2014
2. Jadhav,P.K., Schiffler,M.A., Gavardinas,K., Kim,E.J., Matthews,D.P., Staszak,M.A., Coffey,D.S., Shaw,B.W., Cassidy,K.C., Brier,R.A., Zhang,Y., Christie,R.M., Matter,W.F., Qing,K., Durbin,J.D., Wang,Y. and Deng,G.G.
   Discovery of cathepsin S inhibitor LY3000328 for the treatment of abdominal aortic aneurysm
   ACS Med Chem Lett5, 1138-1142. PubMed  Europe PubMed DOI  I
3. Payne,C.D., Deeg,M.A., Chan,M., Tan,L.H., LaBell,E.S., Shen,T. and DeBrota,D.J.
   Pharmacokinetics and pharmacodynamics of the cathepsin S inhibitor, LY3000328, in healthy subjects
   Br J Clin Pharmacol78, 1334-1342. PubMed  Europe PubMed DOI  I